GCM
ANRO icon

Graham Capital Management’s Alto Neuroscience ANRO Stock Holding History

Graham Capital Management’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-40,199
Closed -$86.8K – 1682
2025
Q1 		$86.8K Sell
40,199
-8,030
-17% -$28.7K ﹤0.01% 1219
2024
Q4 		$204K Buy
+48,229
New +$301K ﹤0.01% 1072

Other funds holding ANRO

AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Graham Capital Management's ANRO Position: Q2 2025 in Review

Graham Capital Management sold out of Alto Neuroscience (ANRO) in Q2 2025, closing a stake of 40,199 shares — an estimated $86.8K sold.

Graham Capital Management first reported a position in ANRO in Q4 2024 and held it in 2 quarters. The position peaked at $204K in Q4 2024. 80 funds tracked by Wall St. Rank hold ANRO as of Q2 2025.

  • Graham Capital Management reported no remaining Alto Neuroscience position as of Q2 2025 after selling out during the quarter.
  • Graham Capital Management sold 40,199 Alto Neuroscience shares in Q2 2025, an estimated $86.8K.
  • Graham Capital Management first reported a position in Alto Neuroscience in Q4 2024 and held it in 2 quarters.
  • Graham Capital Management's Alto Neuroscience position peaked at $204K in Q4 2024.
  • 80 funds tracked by Wall St. Rank held Alto Neuroscience as of Q2 2025.

Based on Graham Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.